Indacaterol plus tiotropium versus tiotropium alone in moderate-to-severe COPD

Phase 3, randomised, double-blind trial of indacaterol, tiotropium and salbutamol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Standardized AUC 5 min to 8 h post-dose for FEV1 at week 12. Started Apr 2009; status: active, not recruiting.